The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I have followed this board for a few years now and genuinely believe we are on the cusp of something special. I have only been invested for the last 3 months and now hold a considerable share holding which I am totally at ease with. I intend to hold for at least 2 years with maybe the odd profit take to balance the books. This is an absolute gem in my opinion and cannot see why some individuals are so negative. DYOR.
Oscar
Well done
Volumes increasing ..3m buys today and looks like Lanstead not reducing below notifiable 15% .
As I said to Lisa any positive news on commercial deals on Lupuzor and CIDP and the anti infective programme would give the SP a massive boost.
The $billion Alora Group still committed to the $25m Phase 3 Lupuzor trial and Simbec-Orion appointed to run both the Lupuzor Phase 3 and CIDP Phase 2/3 trial with guidance submissions in with the FDA on the latter.
I cannot think of an AIM Pharma minnow with the potential upside than Immupharma and don't forget the Anti Infective drugs plus the potential blockbuster in Incanthera.
All for the knockdown price of a few million quid.
Cheers
.
Moneymule888,
Your latest volley of comments only solidifies your position as disconnected from the realities of biotech innovation and the strategic direction of Immupharma. It’s clear now; your approach is not about engaging in constructive critique but peddling unfounded skepticism.
Claiming "there is no product and there never will be" showcases a blatant disregard for Immupharma's documented progress and development pipeline. Your fixation on doom, notably the baseless prediction of Phase III failure, betrays a superficial understanding of the biotech sector and the intricacies of AIM-listed companies.
Your narrative, stripped of substance and clinging to cynicism, has been thoroughly discredited by the facts at hand. It’s evident your commentary stems not from informed analysis but a penchant for spreading discord without merit.
The real laughable aspect here is not Immupharma’s potential or its strategic pursuits but your persistent denial of documented advancements and the broader biotech investment landscape's complexity. As your misleading assertions crumble under the weight of facts, your stance becomes increasingly untenable, revealing a profound lack of understanding of the sector you critique.
Factual communication?
The facts are what they are. They can’t licence their products in the US, in the backend of Syria or Afghanistan.
Why’s that? Because there is no product and there never will be. They have an aim but no way of actually getting there.
You’ll be constantly diluted as shareholders if that’s what you enjoy then keep ploughing your money in.
The fact you rate this as a strong buy is quite frankly laughable. Just wait for the impending Phase III failure whenever that happens. Probs run out of money to print that RNS at that stage.
How pathetic it took shareholders to bombard them for them to speak like they’re some captive prisoner at Gitmo. Horrendous…’strong buy’…let me chuckle.
RNSs aren’t worth the paper they’re written on, especially AIM. Look at the actual facts and decide for yourself what’s happening atm. Yep, pretty much nothing.
DYOR
Moneymule888:
Your continuous dissemination of unfounded narratives around Immupharma necessitates not just a rebuttal, but a decisive correction based on the facts laid out in Immupharma's RNS dated 6 March 2024. Your comments, riddled with inaccuracies, showcase a significant misunderstanding of Immupharma’s strategic positioning, financial health, and advancements, calling for a precise, fact-based clarification.
1. Immupharma's Progress:
Your Assertion: Immupharma has achieved little, with Incanthera as its sole asset of value.
Fact-Check (RNSs including 6 March 2024): This portrayal grossly undermines Immupharma's strategic advancements. The company's development pipeline, especially P140 (Lupuzo) for SLE/Lupus and CIDP, demonstrates a dynamic and robust approach to addressing unmet medical needs. Further, the RNS explicitly highlights active discussions for non-dilutive funding through potential lucrative deals, showcasing proactive financial strategy and execution far from the stagnation you suggest.
2. On Financial Stability:
Your Assertion: Imminent bankruptcy and financial distress loom over Immupharma.
Fact-Check (RNS, 6 March 2024): Contrary to your false and doom-laden forecast, Immupharma explicitly confirms its sufficient financing position for its immediate requirements, with no current plans to raise equity in the capital markets. The company's strategic focus on non-dilutive income further solidifies its financial health, directly countering your narrative of fiscal instability.
3. On the Board’s Efforts:
Your Assertion: The board's efforts are portrayed as ineffective.
Fact-Check (RNS, 6 March 2024): The RNS details a strategic reorganisation and significant cost reductions that have notably strengthened Immupharma’s operational and financial standing. These actions reflect a board effectively navigating the company towards sustainable growth and innovation, contrary to your claims of mismanagement.
4. A Call to Responsible Discourse
Your dissemination of misinformation not only undermines factual discourse but potentially harms the broader investor community. The implications of spreading such baseless claims are severe, underscoring the need for accountability in public communications about publicly traded entities.
If your interpretation of Immupharma’s strategic direction and progress remains misaligned with the clear, documented evidence presented by the company, it may be time to reevaluate your engagement. For those of us committed to Immupharma's future, we remain focused on the promising path ahead, underpinned by innovation, strategic growth, and factual, transparent communication.
Finally a Jeff Bezos's words, "the stock is not the company and the company is not the stock". Though Immupharma is clearly not Amazon, this principle remains relevant, emphasising the importance of distinguishing Immupharma's intrinsic value from its stock performance. https://youtu.be/zzWh26xmy
He’s still here. Currently on holiday travelling New Zealand ta.
Just hope more retail haven’t been sucked in but from the buying volumes it sadly looks like they have. Incanthera is the only real asset IMM have. Incanthera will make millions in profit now that they’re in Watson but sadly IMM is just a massive waste of time, clearly have nothing. 20+ years on. Think you can get us to live on Saturn quicker than IMM can do anything remotely useful.
A good stock to buy today…if you don’t like making money. But DYOR. ATB LTHs
He was predicting ADMINISTRATION. Now he is nowhere to be seen. Strange how he was predicting this.
I'm still in. Going to hold quietly for a very long time.
This is one of the few that could offer ridiculous multiples .
Like a fool, I'm in, hoping Tim was genuine yesterday and the various deals come to fruition in 2024. Way to low a price to ignore based on the portfolio and stage of assets.
Time will tell. I'll give it till end of 2025 and review.
Should see a nice move up and hopefully get us over 2p……deals in the pipeline, but with anything pharma you need patience
Dallo
if there wasn't concerns about a placing or cash levels...then there may not have been an Update ...because clearly Tim wasn't bothered to say anything UNTIL the concerns were voiced ...so I think "doomsday posters" is a bit misplaced ...the End of Year Update was nowhere to be seen and to be fair Tim needed a kicking to actually get something out there
They have a commercial deal which is coming to fruition this year. Be madness to sell now.
Oldbutnowisa.
Just as a reminder
Imm invested £2.25 million into Incanthera ...the market values that ar roughly AT £900 k today ...
Do you still advise to sell now and Take a huge loss ??
If, as the RNS states, our holding is of increasing value, in my view we should NOT wait until we are boracic lint to sell, because at that time, all the world will know how hard up we are and for our private co shares we shall be offered far less,
Far better to reduce our holding by, say, 20 to 30% now and hold that cash for the possible rainy day.
Tim has it all under control. IMM is valuable, don't miss out.
Cauldstream
Cheers
I think a few doomsday posters here had an influence on persuading nervous investors to exit with liquidation/ massive dilution placing rumours which management became aware of and acted accordingly after representations from myself and other investors.
... I will get my £12k back, is when all the trials are complete and Lupozor is available to patients around the world. I need the sp to hit 28p, just to get my money back. Which seems like a 100 years from now, if it survives. Today RNS was released to save the SP hitting 0.0p, nothing new really. They kept quiet for far too long, feels like the damage is already done. In my opinion, the sp will hover around 1p for a long time.
Good luck to all long-term holders, especially to those with high -average sp.
Dallo:
You are wasting your time trying to reason with dedicated naysayers like Lambo and Mystic Mike. I listened to Tim giving his Proactive interview today and found what he had to say persuasive.
I am somewhat glad that these naysayers exist - they help to depress the share price and allow me to continue to buy IMM shares at bargain basement prices - excellent news for me and my limited budget.
So carry on Mystic Mike and snivel away!
I followed 1509 with copl.. £9k that cost me lol ... of all the money I invested that was the most certain I ever was to gain a profit... znd my last lesson never to invest again... lol
Syn..what a nice post... from you... so nice to have friendly comments rather than the usual alphas thrusting their chests... yes wonder what ever happened to eva ?? I've got 145k shares now.. Will not buy more.. would love to get out with a fee quid finally
Mysticmike
A thoroughly scurrilous and inane comment .
So Tim doesn't release a RNS for 3 months so he risks his whole reputation to allow a few mates to make a couple of grand as the volumes on the way down from 1.5p to .9p were miniscule.
We can all buy now at 1.3 /1.4p so what a multi bagger for Tim's mates.
Idiot
Why did Tim not say all this back in December, or Jan at the latest the share price would probably not moved much. His communication timing is so poor hè always gives updates and interviews on the back foot. Everything Tim does is dead slow and reactive rather than proactive, how long have heard from him about the RoW rights. Tim we wish you cared about all shareholders not just your mates, I do wonder if Tim's silence was so his friends could buy shares on the cheap as the value dropped from £1.61 on rthe 20th Dec to 90p yesterday.
Synoogold
I have been here for nearly 9 years now and remember Eva et al.
I have been a critic of McCarthy over the years but I thought he was excellent and measured ( by his standards) in the Proactive interview today.
I have spent the last week urging Immupharma management to issue an update to the market and I think they have delivered a well thought out and reassuring message to Investors and the market.
Tim's belief that Incanthera could be a €100 m company may be slightly OTT but even €50m could see this Immupharma investment valued in excess of the current market cap of Immupharma.
He has nailed his reputation and that of whole management on saying that there will be no dilutive
fund raise and with potential commercial licensing deals allied to the supportive Incanthera financial asset, I believe him.
Immupharma at a market cap of c5m looks like a potentially rewarding investment imho and will buy more tomorrow.
DYOR
ATB to real investors.
Hope u are keeping well halfbutt 😊. I remember the heady days with Eva and Nolupus and 1509 et al.
Yes, this share has been 💩show, but I had a similar nasty kick in the balls with Synairgen !!!!!!
Don’t laugh, but I’m almost tempted to get back in after Tim’s proactive interview 🤔
Hope you and the family are keeping well and healthy. Kind regards and hope you get your money back soon 🔜
I'd pxxs myself laughing if I got my £30k back from this... would be such a laugh... only needs to go to 20p..